Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label HER2. Show all posts
Showing posts with label HER2. Show all posts
Sunday, April 15, 2012

abstract: Researchers find discordance between standard human epidermal growth factor receptor 2 (HER2) testing and HER2 status reported on Oncotype DX - CA: A Cancer Journal for Clinicians

›
Researchers find discordance between standard human epidermal growth factor receptor 2 (HER2) testing and HER2 status reported on Oncotype D...
Friday, March 09, 2012

Activity and resistance of trastuzumab according to different clinical settings

›
Activity and resistance of trastuzumab according to different clinical settings : Publication year: 2012 Trastuzumab , a humanized monocl...
Sunday, February 19, 2012

not yet recruiting: A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 - Full Text View - ClinicalTrials.gov

›
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 This study is not yet open for participant recruitment. Ve...
Friday, February 17, 2012

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

›
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. : Back...
Thursday, January 19, 2012

What Is the Current Standard of Care for Anti-HER2 NEOADJUVANT Therapy in Breast Cancer?

›

Researchers find discordance between standard human epidermal growth factor receptor 2 (HER2) testing and HER2 status reported on Oncotype DX

›
"“Our study on HER2 discordance highlights the fact that one test cannot provide all the answers [regarding optimal treatment for wo...
Monday, June 13, 2011

HER3 - Turning off cancer's growth signals (pancreatic/ovarian)

›
Drugs that interfere with HER3’s better-known cousins, EGFR and HER2, have already proven effective in treating many types of cancer, and ...
Wednesday, February 24, 2010

Editorial: Whither HER2-Related Therapeutics? (breast cancer) -- Journal of Clinical Oncology

›
Note: references to solid tumours "Evidence suggests that most solid tumors, regardless of their type, cannot grow beyond approximatel...
Saturday, February 20, 2010

Full access: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

›
Tuesday, March 17, 2009

Abstract/free full access HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

›
Abstract | HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab ...